KDR and neoplasm: In order to study the consequences of VEGF blockade on 786‐O orthoxenograft tumors, we administered tumor‐bearing mice with anti‐VEGFR2 DC101 (DC) or anti‐human VEGF bevacizumab (Beva) (Fig 1A).